125 related articles for article (PubMed ID: 38073367)
1. Eribulin in metastatic breast cancer: Real world data.
Fernández-Laguna CL; Maray I; Macia-Rivas L; Álvarez-Asteinza C; Fernández-Lastras S; Velasco Durántez V; Carbajales Álvarez M; Lozano-Blázquez A
Breast Dis; 2023; 42(1):349-360. PubMed ID: 38073367
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
Chabot I; Zhao Q; Su Y
Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness, safety, and impact on quality of life of eribulin-based therapy in heavily pretreated patients with metastatic breast cancer: A real-world analysis.
Gui X; Liang X; Li H
Cancer Med; 2023 Aug; 12(16):16793-16804. PubMed ID: 37403746
[TBL] [Abstract][Full Text] [Related]
4. Does the Timing of Eribulin Treatment for Advanced or Metastatic Breast Cancer Matter? Evidence from a Real-World Setting.
Chen CJ; Nguyen HTH; Huang CH; Wang HC; Wu CT; Wu YC; He GY; Chou C; Lin HW; Liu LC
Chemotherapy; 2023; 68(1):23-34. PubMed ID: 36108618
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
[TBL] [Abstract][Full Text] [Related]
7. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
Manso L; Moreno Antón F; Izarzugaza Perón Y; Delgado Mingorance JI; Borrega García P; Echarri González MJ; Martínez-Jañez N; López-González A; Olier Garate C; Ballesteros García A; Chacón López-Muñíz I; Ciruelos Gil E; García-Sáenz JA; Paz-Ares L
Breast J; 2019 Mar; 25(2):219-225. PubMed ID: 30734437
[TBL] [Abstract][Full Text] [Related]
8. Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.
Sabatier R; Diéras V; Pivot X; Brain E; Roché H; Extra JM; Monneur A; Provansal M; Tarpin C; Bertucci F; Viens P; Zemmour C; Gonçalves A
Cancer Res Treat; 2018 Oct; 50(4):1226-1237. PubMed ID: 29281873
[TBL] [Abstract][Full Text] [Related]
9. A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK).
Park MH; Lee SJ; Noh WC; Jeon CW; Lee SW; Son GS; Moon BI; Lee JS; Kang SS; Suh YJ; Gwak G; Kim TH; Yoo YB; Kim HA; Kim MY; Kim JY; Jeong J
Breast; 2020 Dec; 54():121-126. PubMed ID: 32980648
[TBL] [Abstract][Full Text] [Related]
10. Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience - A Multicenter Retrospective Study.
Jafri M; Kristeleit H; Misra V; Baxter M; Ahmed S; Jegannathen A; Jain A; Maskell D; Barthakur U; Edwards G; Walter HS; Walshaw R; Khan M; Borley A; Rea D
Oncology; 2022; 100(12):666-673. PubMed ID: 36044833
[TBL] [Abstract][Full Text] [Related]
11. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
Tolaney SM; Barroso-Sousa R; Keenan T; Li T; Trippa L; Vaz-Luis I; Wulf G; Spring L; Sinclair NF; Andrews C; Pittenger J; Richardson ET; Dillon D; Lin NU; Overmoyer B; Partridge AH; Van Allen E; Mittendorf EA; Winer EP; Krop IE
JAMA Oncol; 2020 Oct; 6(10):1598-1605. PubMed ID: 32880602
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
[TBL] [Abstract][Full Text] [Related]
13. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer.
Goyal RK; Zhang J; Davis KL; Sluga-O'Callaghan M; Kaufman PA
Breast Cancer Res Treat; 2024 May; 205(1):201-210. PubMed ID: 38310616
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
Kikuchi Y; Uchida Y; Shirakawa K; Kanauchi H; Niwa T; Nishioka K; Tada K; Hashimoto M; Yasuda H; Sugiura R; Kawabata H; Seto Y; Ogawa T
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e231-e237. PubMed ID: 29498210
[TBL] [Abstract][Full Text] [Related]
16. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
Yuan P; Hu X; Sun T; Li W; Zhang Q; Cui S; Cheng Y; Ouyang Q; Wang X; Chen Z; Hiraiwa M; Saito K; Funasaka S; Xu B
Eur J Cancer; 2019 May; 112():57-65. PubMed ID: 30928806
[TBL] [Abstract][Full Text] [Related]
17. The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry.
Pouwels XGLV; Geurts SME; Ramaekers BLT; Erdkamp F; Vriens BEPJ; Aaldering KNA; van de Wouw AJ; Dercksen MW; Smilde TJ; Peters NAJB; Riel JMV; Pepels MJ; Heijnen-Mommers J; Joore MA; Tjan-Heijnen VCG; de Boer M
Acta Oncol; 2020 Jan; 59(1):82-89. PubMed ID: 31583931
[No Abstract] [Full Text] [Related]
18. Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.
De Sanctis R; Agostinetto E; Masci G; Ferraro E; Losurdo A; Viganò A; Antunovic L; Zuradelli M; Torrisi RMC; Santoro A
Oncology; 2018; 94 Suppl 1(Suppl 1):19-28. PubMed ID: 30036884
[TBL] [Abstract][Full Text] [Related]
19. Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study.
Oruc Z; Kaplan MA; Geredeli C; Yildirim Sari N; Ozaslan E; Aytekin A; Tamer Elkiran E; Koca S; Dogan M; Turan N; Yuce O; Sevinc A; Ercelep O; Isikdogan A
J BUON; 2019; 24(5):1876-1883. PubMed ID: 31786850
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
